FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:MAP3K9-MED6

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: MAP3K9-MED6
FusionPDB ID: 51361
FusionGDB2.0 ID: 51361
HgeneTgene
Gene symbol

MAP3K9

MED6

Gene ID

4293

10001

Gene namemitogen-activated protein kinase kinase kinase 9mediator complex subunit 6
SynonymsMEKK9|MLK1|PRKE1ARC33|NY-REN-28
Cytomap

14q24.2

14q24.2

Type of geneprotein-codingprotein-coding
Descriptionmitogen-activated protein kinase kinase kinase 9mixed lineage kinase 1 (tyr and ser/thr specificity)mediator of RNA polymerase II transcription subunit 6CTD-2540L5.5activator-recruited cofactor 33 kDa componentrenal carcinoma antigen NY-REN-28
Modification date2020031320200313
UniProtAcc

P80192

Main function of 5'-partner protein: FUNCTION: Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. Plays an important role in the cascades of cellular responses evoked by changes in the environment. Once activated, acts as an upstream activator of the MKK/JNK signal transduction cascade through the phosphorylation of MAP2K4/MKK4 and MAP2K7/MKK7 which in turn activate the JNKs. The MKK/JNK signaling pathway regulates stress response via activator protein-1 (JUN) and GATA4 transcription factors. Plays also a role in mitochondrial death signaling pathway, including the release cytochrome c, leading to apoptosis. {ECO:0000269|PubMed:11416147, ECO:0000269|PubMed:15610029}.

O75586

Main function of 5'-partner protein: FUNCTION: Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors. {ECO:0000269|PubMed:16595664}.
Ensembl transtripts involved in fusion geneENST idsENST00000381250, ENST00000553414, 
ENST00000554146, ENST00000554752, 
ENST00000555993, 
ENST00000556044, 
ENST00000256379, ENST00000430055, 
ENST00000440435, ENST00000554963, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score2 X 2 X 2=83 X 3 X 3=27
# samples 23
** MAII scorelog2(2/8*10)=1.32192809488736log2(3/27*10)=0.15200309344505
effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs).
DoF>8 and MAII>0
Fusion gene context

PubMed: MAP3K9 [Title/Abstract] AND MED6 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: MAP3K9 [Title/Abstract] AND MED6 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)MAP3K9(71216650)-MED6(71060095), # samples:2
MED6(71063328)-MAP3K9(71227899), # samples:2
Anticipated loss of major functional domain due to fusion event.MAP3K9-MED6 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
MAP3K9-MED6 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
MAP3K9-MED6 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
MAP3K9-MED6 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
MED6-MAP3K9 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
MED6-MAP3K9 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
MAP3K9-MED6 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF.
MAP3K9-MED6 seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.
MAP3K9-MED6 seems lost the major protein functional domain in Hgene partner, which is a kinase due to the frame-shifted ORF.
MAP3K9-MED6 seems lost the major protein functional domain in Tgene partner, which is a cell metabolism gene due to the frame-shifted ORF.
MAP3K9-MED6 seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneMAP3K9

GO:0006468

protein phosphorylation

15610029

HgeneMAP3K9

GO:0046777

protein autophosphorylation

15610029

TgeneMED6

GO:0045944

positive regulation of transcription by RNA polymerase II

12037571



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr14:71216650/chr14:71060095)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across MAP3K9 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across MED6 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000554752MAP3K9chr1471216650-ENST00000554963MED6chr1471060095-1845115001625541
ENST00000554752MAP3K9chr1471216650-ENST00000256379MED6chr1471060095-2841115001616538
ENST00000554752MAP3K9chr1471216650-ENST00000430055MED6chr1471060095-2365115001637545
ENST00000554752MAP3K9chr1471216650-ENST00000440435MED6chr1471060095-1789115001421473
ENST00000555993MAP3K9chr1471216650-ENST00000554963MED6chr1471060095-220815133631988541
ENST00000555993MAP3K9chr1471216650-ENST00000256379MED6chr1471060095-320415133631979538
ENST00000555993MAP3K9chr1471216650-ENST00000430055MED6chr1471060095-272815133632000545
ENST00000555993MAP3K9chr1471216650-ENST00000440435MED6chr1471060095-215215133631784473
ENST00000381250MAP3K9chr1471216650-ENST00000554963MED6chr1471060095-218014853351960541
ENST00000381250MAP3K9chr1471216650-ENST00000256379MED6chr1471060095-317614853351951538
ENST00000381250MAP3K9chr1471216650-ENST00000430055MED6chr1471060095-270014853351972545
ENST00000381250MAP3K9chr1471216650-ENST00000440435MED6chr1471060095-212414853351756473

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000554752ENST00000554963MAP3K9chr1471216650-MED6chr1471060095-0.0048369280.9951631
ENST00000554752ENST00000256379MAP3K9chr1471216650-MED6chr1471060095-0.0006693850.99933064
ENST00000554752ENST00000430055MAP3K9chr1471216650-MED6chr1471060095-0.0020615750.99793845
ENST00000554752ENST00000440435MAP3K9chr1471216650-MED6chr1471060095-0.0041648150.9958352
ENST00000555993ENST00000554963MAP3K9chr1471216650-MED6chr1471060095-0.0069334720.99306655
ENST00000555993ENST00000256379MAP3K9chr1471216650-MED6chr1471060095-0.0010659810.998934
ENST00000555993ENST00000430055MAP3K9chr1471216650-MED6chr1471060095-0.0031694920.9968305
ENST00000555993ENST00000440435MAP3K9chr1471216650-MED6chr1471060095-0.005154540.9948455
ENST00000381250ENST00000554963MAP3K9chr1471216650-MED6chr1471060095-0.0073531730.9926468
ENST00000381250ENST00000256379MAP3K9chr1471216650-MED6chr1471060095-0.001088250.99891174
ENST00000381250ENST00000430055MAP3K9chr1471216650-MED6chr1471060095-0.0032411490.9967589
ENST00000381250ENST00000440435MAP3K9chr1471216650-MED6chr1471060095-0.0054095030.9945905

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for MAP3K9-MED6

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide

Top

Potential FusionNeoAntigen Information of MAP3K9-MED6 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)

Top

Potential FusionNeoAntigen Information of MAP3K9-MED6 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of MAP3K9-MED6

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of MAP3K9-MED6

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score

Top

Vaccine Design for the FusionNeoAntigens of MAP3K9-MED6

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of MAP3K9-MED6

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample

Top

Potential target of CAR-T therapy development for MAP3K9-MED6

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to MAP3K9-MED6

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to MAP3K9-MED6

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource